Antioxidants in patients living with HIV on antiretrovirals
Autoři | |
---|---|
Rok publikování | 2021 |
Druh | Článek v odborném periodiku |
Časopis / Zdroj | MILITARY MEDICAL SCIENCE LETTERS - VOJENSKÉ ZDRAVOTNICKÉ LISTY |
Fakulta / Pracoviště MU | |
Citace | |
www | https://www.mmsl.cz/magno/mms/2021/mn2.php |
Doi | http://dx.doi.org/10.31482/mmsl.2021.005 |
Klíčová slova | Antiretroviral therapy; glutathione; HIV; oxidative stress |
Přiložené soubory | |
Popis | Introduction Oxidative stress is considered predictors of diseases associated with aging (cardiovascular disease, neurodegenerative disease, malignancies, and others) in HIV-negative general population. Antioxidants were investigated in people living with HIV on antiretroviral treatment to determine whether they had an immunosenescent phenotype that might predispose to the development of premature age-related diseases. Clinical studies in this population are controversial. Methods The study was conducted among 213 subjects with HIV, including 172 subjects on antiretrovirals and 41 subjects before the initiation of treatment. The control group consisted of healthy HIV-negative adults. We compared the reduced glutathione and ferric reducing antioxidant power levels in HIV untreated and treated patients and controls. Significant differences were determined by appropriate statistical tests (t-test, Mann–Whitney U test, Kolmogorov–Smirnov test, ANOVA, Kruskal–Wallis test). Relationships between continuous variables were quantified using Spearman’s rank correlation coefficient. Results Glutathione levels were significantly lower in the treated group compared with the untreated group and controls (P ? 0.001). Differences in total antioxidant levels between groups were not found. Conclusions Significant decrease of antioxidants was found independent of the virologic status of HIV patients on antiretroviral treatment. Persistence of these abnormal parameters may contribute and predispose to the premature development of diseases associated with aging. |